Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting
BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous an...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , |
| التنسيق: | article |
| منشور في: |
2024
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1016/j.vaccine.2024.06.010 https://www.sciencedirect.com/science/article/pii/S0264410X24006698 http://hdl.handle.net/10576/58683 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1857415085967802368 |
|---|---|
| author | Salma, Younes |
| author2 | Nicolai, Eleonora Younes, Nadin Pieri, Massimo Bernardini, Sergio Nizamuddin, Parveen B. Al-Sadeq, Duaa W. Daas, Hanin I. Ismail, Ahmed Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. |
| author2_role | author author author author author author author author author author author |
| author_facet | Salma, Younes Nicolai, Eleonora Younes, Nadin Pieri, Massimo Bernardini, Sergio Nizamuddin, Parveen B. Al-Sadeq, Duaa W. Daas, Hanin I. Ismail, Ahmed Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. |
| author_role | author |
| dc.creator.none.fl_str_mv | Salma, Younes Nicolai, Eleonora Younes, Nadin Pieri, Massimo Bernardini, Sergio Nizamuddin, Parveen B. Al-Sadeq, Duaa W. Daas, Hanin I. Ismail, Ahmed Yassine, Hadi M. Abu-Raddad, Laith J. Nasrallah, Gheyath K. |
| dc.date.none.fl_str_mv | 2024-09-10T04:22:26Z 2024-06-05 |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://dx.doi.org/10.1016/j.vaccine.2024.06.010 0264410X https://www.sciencedirect.com/science/article/pii/S0264410X24006698 http://hdl.handle.net/10576/58683 |
| dc.language.none.fl_str_mv | en |
| dc.publisher.none.fl_str_mv | Elsevier |
| dc.rights.none.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologous mRNA vaccination Neutralizing antibody Anti-S1 IgA |
| dc.title.none.fl_str_mv | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. MethodThe study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. ResultsThe study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). ConclusionThe study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | qu_9af10874a0bc1fcbded6323b9ff70d0c |
| identifier_str_mv | 0264410X |
| language_invalid_str_mv | en |
| network_acronym_str | qu |
| network_name_str | Qatar University repository |
| oai_identifier_str | oai:qspace.qu.edu.qa:10576/58683 |
| publishDate | 2024 |
| publisher.none.fl_str_mv | Elsevier |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| spelling | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boostingSalma, YounesNicolai, EleonoraYounes, NadinPieri, MassimoBernardini, SergioNizamuddin, Parveen B.Al-Sadeq, Duaa W.Daas, Hanin I.Ismail, AhmedYassine, Hadi M.Abu-Raddad, Laith J.Nasrallah, Gheyath K.AZD1222 (Oxford-AstraZeneca, ChAd)HomologousHeterologousmRNA vaccinationNeutralizing antibodyAnti-S1 IgABackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. MethodThe study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. ResultsThe study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). ConclusionThe study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels.GKN would like to acknowledge the funding from WHO grant number COVID-19-22-43 and Qatar University grant No. QUCG-BRC-23/24-170. This work was also made possible by grants number UREP29-026-3-004 and UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.Elsevier2024-09-10T04:22:26Z2024-06-05Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.vaccine.2024.06.0100264410Xhttps://www.sciencedirect.com/science/article/pii/S0264410X24006698http://hdl.handle.net/10576/58683enhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:qspace.qu.edu.qa:10576/586832024-09-10T19:06:44Z |
| spellingShingle | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting Salma, Younes AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologous mRNA vaccination Neutralizing antibody Anti-S1 IgA |
| status_str | publishedVersion |
| title | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_full | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_fullStr | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_full_unstemmed | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_short | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_sort | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| topic | AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologous mRNA vaccination Neutralizing antibody Anti-S1 IgA |
| url | http://dx.doi.org/10.1016/j.vaccine.2024.06.010 https://www.sciencedirect.com/science/article/pii/S0264410X24006698 http://hdl.handle.net/10576/58683 |